Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain zapping tailored to you: new study targets depression and anxiety

NCT ID NCT05437705

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study at the University of Pennsylvania is testing whether personalized brain stimulation can reduce negative emotions in people with depression and anxiety. Researchers will use brain scans to map each participant's negative emotion patterns, then apply different types of transcranial magnetic stimulation (TMS) to find the best frequency for disrupting those patterns. The goal is to see if the optimal stimulation can improve symptoms like rumination over two 3-day sessions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Transcranial Magnetic Stimulation (TMS)
What this could lead to
If successful, this could lead to a personalized brain stimulation treatment that reduces rumination and negative emotions in people with depression or anxiety.
What could go wrong
This is an early-stage study with only 40 participants, so results may not apply to everyone. The optimal stimulation frequency may not work better than the least optimal one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. 18-65 years old 2. Patient Health Questionnaire (PHQ-9 score) = or \> than 10 3. Comprehension of instructions in the English language. 4. Capacity to provide informed consent and follow study procedures. 5. Availability for the duration of the study. Exclusion Criteria: 1. Diagnosis of bipolar disorder (as PI discretion), schizophrenia or other psychotic disorder 2. Recent use of psychoactive medications or substances as determined by investigators 3. History of neurological disorder or traumatic brain injury (other than mild) 4. Unable to have an MRI scan, or current or prior medical condition that could interfere with the collection or interpretation of MRI data 5. Unable to receive or tolerate TMS 6. Implanted devices, such as an aneurysm clip or cardiac pacemaker 7. History of stroke, epilepsy, or brain scarring 8. Pregnant, nursing, or trying to become pregnant (self-attestation alone) During this study, participants are asked to: 1. Refrain from substance use (including marijuana and illicit drugs) for duration of the study (self-attestation alone). 2. Abstain from alcohol for 24 hours before the MRI scans (self-attestation alone). 3. Abstain from increasing caffeine intake or begin taking any new medications (self-attestation alone).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.